Impact of prior azacitidine on the outcome of allogeneic hematopoietic transplantation for myelodysplastic syndrome

Oshikawa, Gaku; Yoshioka, Kousuke; Takahashi, Yusuke; Shingai, Naoki; Ikegawa, Shuntaro; Kobayashil, Takeshi; Doki, Noriko; Kakihana, Kazuhiko; Ohashi, Kazuteru; Sakamaki, Hisashi

doi:10.1007/s12253-015-9933-8

Cited by 9 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The impact of azacitidine before allo-SCT for MDS has been evaluated in a retrospective study, comparing the outcome of 15 MDS patients treated with azacitidine before allo-SCT to that of 52 patients who received BSC only [8]. No significant differences in OS, disease-free survival (DFS), cumulative incidence of relapse (CIR), or nonrelapse mortality were observed.…”

Section: Introductionmentioning

confidence: 99%

Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia

Voso

Fianchi

2015

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia

Voso

Fianchi

2015

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

“…Voso et al also found that AZA treatment before transplantation was beneficial if patients reached CR [38]. While no significant difference was found between pre-SCT AZA responders and non-responders in OS and RFS in another research [23]. There were also researches claimed that pretransplantation therapy may favor the selection of resistant clones.…”

Section: Discussionmentioning

confidence: 96%

“…Among them, the excluded studies were used as meeting summaries, and 28 were excluded. Because of insufficient data or irrelevant results, the final 7 studies were included in the meta-analysis [21][22][23][24][25][26][27].…”

Section: Study Selectionmentioning

confidence: 99%

Meta-analysis of the benefit of hypomethylating agents before allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes

et al. 2021

View full text Add to dashboard Cite

Hypomethylating agents (HMAs) are effective therapies in myelodysplastic syndromes (MDS), but allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only way to cure MDS. According to the current literature, it is difficult to confirm whether HMAs bridging therapy is beneficial for MDS patients receiving allo-HSCT. Therefore, we tried to evaluate the effect of HMAs on long-term survival of the MDS patients. Databases, including PubMed, Embase Ovid, and the Cochrane Library, were searched for studies published up to January 10, 2021. Patients who accepted HMAs bridging to allo-HSCT were defined as experimental group, while patients who received the best supportive care (BSC) before allo-HSCT were control group. Overall survival (OS) was the primary end point. Seven studies were included in the final analysis. The final results showed no OS differences between patients accepted HMAs before allo-HSCT and those received BSC (HR = 0.86, 95% CI: 0.64–1.15, p = 0.32), indicating that MDS patients' long-term survival did not benefit from HMAs bridging therapy before allo-HSCT. This conclusion needs to be further verified by a large number of prospective randomized controlled trials, which have guiding significance for the treatment of MDS patients.

show abstract

“…10 retrospectively reviewed clinical outcome of 15 MDS patients who were treated with AZA before allo-SCT (AZA group) compared with 52MDS patients who were solely given the best supportive care (BSC) before allo-SCT (BSC group). Although patients in the AZA group were older with higher IPSS scores compared to patients in the BSC group, no significant differences were found between the two groups in OS; 79.0 and 78.6%, disease-free survival (DFS); 71.2 and 59.2%, cumulative incidence of relapse; 15.4 and 11.3% or non-relapse mortality; 21.0 and 13.5%, at 1 year.…”

Section: Discussionmentioning

confidence: 99%

Bridging-to-Transplant with Azacitidine for Myelodysplastic Syndrome and Acute Myeloid Leukemia, Reduces the Incidence of Acute Graft-versus-Host Disease

et al. 2017

View full text Add to dashboard Cite

Allogeneic stem cell transplantation (allo-SCT) is the only curative option for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Azacitidine (AZA) has a good toxicity profile compared with intensive chemotherapy and can be considered a pre-transplant regimen in elderly patients and in patients with comorbidities. To investigate the impact of pre-transplant AZA on patient outcome after allo-SCT, we conducted a retrospective analysis of AZA pre-treatment followed by allo-SCT in patients with high-risk MDS and AML. Twenty patients who were divided into two groups according to AZA treatment given prior to allo-SCT (AZA vs non-AZA group, 10 each). Overall survival, event-free survival and incidence of chronic graft-versus-host disease (GVHD) were not significantly different between the two groups. The overall incidence of grade II to IV acute GVHD in the AZA group was significantly lower than that in the non-AZA group (P=0.004). Bridging to transplant with AZA should be considered as an immunomodulator and effective treatment strategy for patients with MDS and AML.

show abstract

Impact of prior azacitidine on the outcome of allogeneic hematopoietic transplantation for myelodysplastic syndrome

Cited by 9 publications

References 17 publications

Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia

Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia

Meta-analysis of the benefit of hypomethylating agents before allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes

Bridging-to-Transplant with Azacitidine for Myelodysplastic Syndrome and Acute Myeloid Leukemia, Reduces the Incidence of Acute Graft-versus-Host Disease

Contact Info

Product

Resources

About